E-viri
Recenzirano
-
Gómez-Zorrilla, Silvia; Becerra-Aparicio, Federico; Sendra, Elena; Zamorano, Laura; Grau, Inmaculada; Pintado, Vicente; Padilla, Belén; Benito, Natividad; Boix-Palop, Lucía; Fariñas, Maria Carmen; Peñaranda, María; Gamallo, Maria Rocío; Martinez, Jose Antonio; Morte-Romea, Elena; Del Pozo, Jose Luis; Montesinos, Inmaculada López; Durán-Jordà, Xavier; Ponz, Ricardo; Cotarelo, Manuel; Cantón, Rafael; Oliver, Antonio; Ruiz-Garbajosa, Patricia; Horcajada, Juan Pablo; Siverio, Ana; Montesinos, Inmaculada López; Gijón, Desiré; Merino, Irene; López de Gopegui, Enrique; López-Causapé, Carla; Sabé, Nuria; Shaw, Evelyn; Berbel, Dámaris; Quintano, Fe Tubau; Carrillo, Carlos Sánchez; Cercenado, Emilia; Rubio, Verónica; Rivera, Alba; Calvo, Esther; Badía, Cristina; Xercavins, Mariona; de Malet, Ana; Canoura-Fernández, Luis; Salvo, Soledad; Paño-Pardo, Jose Ramón; Carmona-Torre, Francisco
The Journal of hospital infection, 06/2024Journal Article
The global burden associated with antimicrobial resistance is of increasing concern. The aim of this study was to evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated (HCA) bacteremic urinary tract infections (BUTI). This is a post-hoc analysis a prospective multicenter study of patients with HCA-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48-72h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (OR 3.13, 95% CI 2.11-4.69, p<0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa etiology (OR 7.84, 95% CI 2.37-25.95; p=0.001). MDR was independently associated with prior use of fluoroquinolones (aOR 2.43; 95% CI 1.25-4.69), cephalosporins (aOR 2.14; 95% CI 1.35-3.41) and imipenem or meropenem (aOR 2.08; 95% CI 1.03-4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but with longer hospital stay. MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although was independently associated with longer duration of hospital stay.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.